drugset / Trial / NCT00088062
STA-5326 in Crohn's Disease Patients
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine the safety and tolerability of STA-5326 given once daily or twice daily to Crohn's Disease patients with moderate disease.
Timeline
- Start
- 2004-02
- Primary completion
- —
- Completion
- 2004-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | STA-5326 | Unknown | — | — |